Avian influenza (AI) has become a disease of great importance for human and animal health. Beside adverse sideeffects, there is resistance mutation for about all the conventional drugs that target viral proteins. This studyaimed to evaluate antiviral activity of silver nanoparticles combined with epigallocatechingallate (EGCG-AgNPs)and co-administered with zinc sulphate (Zn+2) as alternative treatment strategy to control AI H9N2. EGCGconjugated silver nanoparticles (EGCG-AgNPs) were synthesized. Virus propagation was performed usingembryonated Specific-Pathogen-Free (SPF) hen’s eggs. Viral EID50 titers were determined before and aftertreatments. The antiviral activity was determined as Log virucidal reduction. A commercial tetrazolium MTSassay kit was used to determine cytotoxicity. Results showed that 50 μM EGCG was the most significant concentrationreduced the logEID50/mL of AI H9N2. Co-treatment with zinc sulphate (1.3 mg/mL) increased theEGCG antiviral effect. The most effective antiviral activity was obtained when combined EGCG-AgNPs with zincsulphate with the greatest virucidal log reduction. No cytotoxic effect in Vero cells was observed among all ofthese forms at concentrations of interest used in this study. In conclusion, the topical application of EGCGAgNPs/ZnSO4 demands additional antiviral strategies against H9N2 AI. This combination may prevent virustransmission, inhibit virus replication within neighboring cells and inhibit microbial resistance by making microbialadaptability very difficult.